Ana Slipicevic

List of Publications by Year
in descending order

19 papers	614 citations	687220 13 h-index	794469 19 g-index
19 all docs	19 docs citations	19 times ranked	1160 citing authors

#	Article	IF	Citations
1	High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PLoS ONE, 2012, 7, e38254.	1.1	115
2	Expression of Activated Akt and PTEN in Malignant Melanomas. American Journal of Clinical Pathology, 2005, 124, 528-536.	0.4	93
3	The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer, 2008, 8, 276.	1.1	66
4	Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecologic Oncology, 2014, 135, 118-124.	0.6	59
5	Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer, 2015, 15, 462.	1.1	43
6	KIT in Melanoma: Many Shades of Gray. Journal of Investigative Dermatology, 2015, 135, 337-338.	0.3	32
7	Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochemical and Biophysical Research Communications, 2005, 329, 266-274.	1.0	30
8	Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer, 2012, 12, 73.	1.1	28
9	Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Human Pathology, 2009, 40, 527-537.	1.1	23
10	Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Scientific Reports, 2017, 7, 5081.	1.6	23
11	Biological effects induced by insulinâ€like growth factor binding protein 3 (IGFBPâ€3) in malignant melanoma. International Journal of Cancer, 2010, 126, 350-361.	2.3	20
12	Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biology and Therapy, 2013, 14, 146-154.	1.5	18
13	Expression of CDK1Tyr15, pCDK1Thr161, Cyclin B1 (Total) and pCyclin B1Ser126 in Vulvar Squamous Cell Carcinoma and Their Relations with Clinicopatological Features and Prognosis. PLoS ONE, 2015, 10, e0121398.	1.1	15
14	MX 2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell and Melanoma Research, 2020, 33, 446-457.	1.5	11
15	MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Human Pathology, 2016, 54, 74-81.	1.1	10
16	Evaluation of <scp>CHK</scp>1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro. Cancer Medicine, 2018, 7, 3955-3964.	1.3	8
17	Cellular localization of <scp>CIP</scp>2A determines its prognostic impact in superficial spreading and nodular melanoma. Cancer Medicine, 2015, 4, 903-913.	1.3	7
18	Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leukemia Research, 2021, 101, 106499.	0.4	7

#	Article	IF	Citations
19	MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Medicine, 2021, 10, 2840-2854.	1.3	6